Premium
Relapse of minimal change nephrotic syndrome after intravitreal bevacizumab
Author(s) -
Sato Tomoko,
Kawasaki Yukihiko,
Waragai Tomoko,
Imaizumi Tomoko,
Ono Atsushi,
Sakai Nobuko,
Hosoya Mitsuaki
Publication year - 2013
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1111/ped.12017
Subject(s) - bevacizumab , medicine , proteinuria , prednisolone , nephrotic syndrome , monoclonal , vascular endothelial growth factor , ophthalmology , choroidal neovascularization , antibody , monoclonal antibody , chemotherapy , vegf receptors , retinal , immunology , kidney
Reported herein is a case of relapse of nephrotic syndrome ( NS ) after intravitreal injection of beva cizumab, a monoclonal antibody that binds to vascular endothelial growth factor ( VEGF) , in a 16‐year‐old girl. She had a diagnosis of steroid‐dependent NS and had been treated with prednisolone, and remained in remission. The patient had had visus brevior 10 years previously, and was diagnosed with severe myopic choroidal neovascularization (m CNV ). Intravitreal bevacizumab was given for m CNV . At 9 days after intravitreal injection of bevacizumab, proteinuria was positive. The patient had relapse of NS caused by bevacizumab, and steroid pulse therapy was then given and the proteinuria resolved. It is necessary to take particular care to prevent NS relapses in patients with m CNV treated with intravitreal bevacizumab.